Direkt zum Inhalt
Merck
  • Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.

Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.

European journal of medicinal chemistry (2008-02-06)
Regina Appiah-Opong, Iwan de Esch, Jan N M Commandeur, Mayagustina Andarini, Nico P E Vermeulen
ZUSAMMENFASSUNG

Inhibition of cytochrome P450 (CYP) is a major cause of drug-drug interactions. In this work, inhibitory potentials of 33 curcumin analogues, i.e. 2,6-dibenzylidenecyclohexanone (A series), 2,5-dibenzylidenecyclopentanone (B series) and 1,4-pentadiene-3-one (C series) substituted analogues of curcumin towards recombinant human CYP1A2, CYP3A4, CYP2B6, CYP2C9 and CYP2D6, all important for drug metabolism, were studied in vitro. Fluorescence plate reader and high performance liquid chromatography (HPLC) assays were used to evaluate CYP-inhibitory activities. MOE-based Quantitative structure-activity relationship (QSAR) analysis suggested that electrostatic and hydrophobic interactions and lipophilicity are important factors for CYP inhibition. Apart from insights in important molecular properties for CYP inhibition, the present results may also guide further design of curcumin analogues with less susceptibility to drug-drug interactions.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
trans,trans-Dibenzylidenaceton, 98%